Efficacy and Safety

Learn how Galliprant® (grapiprant tablets) treatment has proven effective in a placebo-controlled study of 285 client-owned dogs.1

1a-owner-stroking-dog-Gal-750 x 562

Study Design1

In a placebo-controlled and randomized study, 285 dogs were enrolled to evaluate the effectiveness of Galliprant in the treatment of osteoarthritis pain.

Galliprant was prescribed to dogs ranging in age from 2 to 16.75 years old, weighing 9 to 131 pounds, with radiographic and clinical signs of OA. Galliprant was dosed at 2 mg/kg once daily for 28 days, alongside a vehicle-controlled group.

3a-Elanco-small-dog-on-sofa-Gal-6720 x 4480


Dogs were assessed for improvements in pain and function by their owners, using the Canine Brief Pain Inventory (CBPI) scoring system on days 0, 7, 14, 21 and 28. A veterinary assessment also occurred at screening and on days 14 and 28.

For evaluation of improvement in chronic pain, pet owner assessments are critical to detect improvements in mobility and pain in the home environment. The CBPI is a validated questionnaire that asks dogs owners four questions about the severity of pain evident in a dog (severity score), and six questions about how pain interferes with a dog’s activity level (interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g. medication or surgery).

6a-Elanco-small-dog-w-owner-Gal-6720 x 4480

Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21, and 28*, and in veterinary assessments.

*Primary endpoint.


The following adverse reactions were observed:

Adverse reaction** - Vomiting
Galliprant (grapiprant tablets)
N = 141 - 24
Vehicle control (tablets minus grapiprant)
N = 144 - 9
Adverse reaction** - Diarrhea, soft stool
Galliprant (grapiprant tablets)
N = 141 - 17
Vehicle control (tablets minus grapiprant)
N = 144 - 13
Adverse reaction** - Anorexia, inappetence
Galliprant (grapiprant tablets)
N = 141 - 9
Vehicle control (tablets minus grapiprant)
N = 144 - 7
Adverse reaction** - Lethargy
Galliprant (grapiprant tablets)
N = 141 - 6
Vehicle control (tablets minus grapiprant)
N = 144 - 2
Adverse reaction** - Immune mediated hemolytic anemia
Galliprant (grapiprant tablets)
N = 141 - 1
Vehicle control (tablets minus grapiprant)
N = 144 - 0
Adverse reaction** - Buccal ulcer
Galliprant (grapiprant tablets)
N = 141 - 1
Vehicle control (tablets minus grapiprant)
N = 144 - 0

**Dogs may have experienced more than one type or occurrence during the study.

The results from this clinical study demonstrated that Galliprant, administered at 2 mg/kg once daily for 28 days, was effective for the control of pain and inflammation associated with canine OA.

Kirby Shaw
I feel comfortable choosing Galliprant as a first-line option for my OA cases.

Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, CCRT, DACVSMR

You Might Be Interested In…

Learn how to make Galliprant a part of your canine OA protocol.

8a-vet-smiling-in-clinic-500 x 290

Supporting Your Canine OA Protocol

See how we can support your success when it comes to diagnosing and treating your patients with canine OA.

6c-vet-smiling-on-chair-Gal-500 x 290

A Case of Inspiration

Feel inspired by the stories of veterinarians making a meaningful impact in the lives of their patients and the families.

4a-pack-20mg-60mg-100-90ct-Gal-750 x 562.jpg

Treat Canine OA Pain With Confidence

Find out how Galliprant® (grapiprant tablets) allows you to provide daily relief for canine OA pain.


Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.

Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.

Connect with Galliprant

Let’s keep in touch

© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.